Table 1. Demographic characteristics (N=117).
| Characteristics | Value |
|---|---|
| Age at diagnostic (years) | |
| Mean ± SD | 67.6±11.0 |
| Median (Q1, Q3) | 67.5 (61.3, 74.9) |
| Min, max | 41.4, 93.9 |
| Sex, n (%) | |
| Female | 37 (31.6) |
| Male | 80 (68.4) |
| Tumour histology, n (%) | |
| Adenocarcinoma | 86 (73.5) |
| Squamous cell carcinoma | 24 (20.5) |
| Other | 7 (6.0) |
| PD-L1 tumour proportion score, n (%) | |
| <50% | 30 (31.3) |
| ≥50% | 66 (68.8) |
| Missing | 21 |
| Stage TNM 8th edition, n (%) | |
| III | 20 (17.1) |
| IIIA | 1 |
| IIIB | 13 |
| IIIC | 6 |
| IV | 97 (82.9) |
| Treatment line, n (%) | |
| 1 | 53 (45.3) |
| 2+ | 64 (54.7) |
| Anti-PD-1 antibody, n (%) | |
| Nivolumab | 44 (37.6) |
| Pembrolizumab | 73 (62.4) |
| Smoking status, n (%) | |
| Current | 36 (31.0) |
| Never | 9 (7.8) |
| Former | 71 (61.2) |
| Missing | 1 |
| Months of prior exposure to immunotherapy before switching | |
| Mean ± SD | 7.7±9.8 |
| Median (Q1, Q3) | 7.7 (4.5, 15.9) |
| Min, max | 0.0, 49.1 |
| Location of metastasis, n (%) | |
| Pleural | 20 (17.1) |
| Bone | 23 (19.7) |
| Liver | 13 (11.1) |
| Pericardium | 6 (5.1) |
| Brain | 29 (24.8) |
| Adrenal glands | 24 (20.5) |
| Lung | 30 (25.6) |
| Kidney | 1 (0.9) |
| Digestive tract | 1 (0.9) |
| Lymph nodes | 7 (6.0) |
PD-L1, programmed death-ligand 1; TNM, Tumor Node Metastasis; PD-1, programmed cell death protein 1; SD, standard deviation.